Figure 5. Involvement of Bcl-2, specifically BH3 domain, in STAT3^pTyr705.

A. HeLa cells stably overexpressing either the control vector (HeLa/Neo) or Bcl-2 (HeLa/Bcl-2) were treated with different doses of Bcl-2 specific BH3 mimetic ABT-199 for 24 hours and the lysates were probed for STAT3^pTyr705 & STAT3^pSer727, total STAT3, Bcl-2^pSer70, total Bcl-2, Rac1 and β-actin. B. Densitometry and statistical analyses of the changing ratio between STAT3^pTyr705 and total STAT3 in HeLa/Bcl-2 are represented graphically. * and ** denoting P-value < 0.05 and < 0.02 respectively. C. CEM cells stably overexpressing either the control vector (CEM/Neo) or Bcl-2 (CEM/Bcl-2) were treated with different doses of Bcl-2 specific BH3 mimetic ABT-199 for 24 hours and the lysates were probed for STAT3^pTyr705, total STAT3, Bcl-2^pSer70, total Bcl-2, and β-actin. D. Densitometry and statistical analyses of the changing ratio between STAT3^pTyr705 and total STAT3 in CEM/Bcl-2 are represented graphically. ** denoting P-value < 0.02 respectively E. Effects of Bcl-2 silencing with 2 different SiRNA sequences in CEM/Neo and CEM/Bcl-2 cells on STAT3^pTyr705 following 48 hours. Lysates were probed for STAT3^pTyr705, total STAT3, Bcl-2^pSer70, total Bcl-2, and β-actin.